Home LiteratureArticle Details
PMID: 8690044 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.

Experimental hematology ·Vol. 24 ·No. 8 ·1996-07-00 ·Pages 868-74

Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F

Abstract

We have studied the effects of several interleukin-1 (IL-1) inhibitors--IL-1 receptor antagonist (IL-1ra), soluble IL-1 receptor (sIL-1R) types I and II, and neutralizing monoclonal antibody (mAb) specific for IL-1 receptor type I--on the osteoclast-activating factor (OAF) activity of recombinant IL-1beta and of culture supernatants of unfractionated bone marrow mononuclear cells from multiple myeloma (MM) patients. The latter activity sharply correlated with the IL-1 content of culture supernatants (r = 0.949; p < 0.001). IL-1ra and sIL-1R types I and II had a clear-cut modulating effect on the OAF activity of IL-1beta at saturating doses (2-10 ng/mL); their effect was evident at 2 ng/mL and was dose-dependent over a large range of concentrations. Similarly, the three reagents neutralized the OAF activities of all MM cell supernatants in a dose-dependent fashion and completely abolished them when tested at the fixed concentration of 5 nM. The bone-resorbing activity of tumor necrosis factor-alpha (TNF-alpha) or lymphotoxin (LT), tested alone or added to MM cell supernatants, was affected not at all by IL-1ra and only minimally by sIL-1R types I and II, suggesting that little or no endogenous IL-1 was produced by the rat cells in the assay under TNF-alpha or LT stimulation. Consistent with these findings, PGE2 production elicited by IL-1beta or IL-1-rich supernatants in the rat long-bone assay was abolished by each reagent. Also, mAbs to the IL-1R p80 (type I) chains could modulate the effects of IL-1--recombinant or plasma cell-derived--in the OAF assay, but their activity was markedly less pronounced when compared with the IL-1 inhibitors, since they could never completely abolish bone resorption. Taken together, these findings demonstrate that inhibition of IL-1 interaction with cognate surface receptors on bone cells effectively counteracts its biologic activity. The findings also strongly indicate that OAF activity in conditioned medium of unfractionated myeloma bone marrow cells is predominantly, if not solely, related to IL-1beta.

MeSH Terms
Animals Antibodies, Monoclonal Bone Marrow/drug effects,pathology Bone Marrow Cells Bone Resorption Calcium/metabolism Cell Division/drug effects Cells, Cultured Humans Interleukin 1 Receptor Antagonist Protein Interleukin-1/antagonists & inhibitors,pharmacology,physiology Lymphokines/immunology,physiology Lymphotoxin-alpha/pharmacology Multiple Myeloma/pathology Neoplasm Staging Osteoclasts/drug effects,physiology Rats Recombinant Proteins/pharmacology Sialoglycoproteins/pharmacology Tumor Necrosis Factor-alpha/pharmacology
Chemicals
Antibodies, Monoclonal IL1RN protein, human Interleukin 1 Receptor Antagonist Protein Interleukin-1 Lymphokines Lymphotoxin-alpha Recombinant Proteins Sialoglycoproteins Tumor Necrosis Factor-alpha osteoclast activating factor Calcium
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Torcia M
Department of Experimental Medicine, University of Roma Tor Vergata, Italy.
Lucibello M
Vannier E
Fabiani S
Miliani A
Guidi G
Spada O
Dower S K
Sims J E
Shaw A R
Dinarello C A
Garaci E
Cozzolino F
Article Info
Journal
Experimental hematology
Abbr.
Exp Hematol
ISSN
0301-472X
Published
1996-07-00
Pages
868-74
Language
English
Region
Netherlands
NLM ID
0402313
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]